Medical Dermatology Specialists /ID# 262915
Welcome,         Profile    Billing    Logout  
 8 Trials 
119 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Coordinator, Site
NCT04041050: A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Active, not recruiting
1
85
Europe, Japan, US, RoW
Navitoclax, ABT-263, Ruxolitinib, Celecoxib, Celebrex
AbbVie
Myeloproliferative Neoplasm
01/25
01/25
NCT04707248: A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Recruiting
1
180
Japan, US
DS-6000a, R-DXd
Daiichi Sankyo, Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Ovarian Tumor
11/24
11/24
YL202-INT-101-01, NCT05653752: A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Active, not recruiting
1
80
US, RoW
YL202
MediLink Therapeutics (Suzhou) Co., Ltd.
Non Small Cell Lung Cancer, Breast Cancer
12/24
12/25
NCT03821935: Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
362
Europe, Canada, Japan, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181
AbbVie
Advanced Solid Tumors Cancer
06/27
06/27
NCT05005403: Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

Recruiting
1
268
Japan, US, RoW
ABBV-514, Budigalimab, ABBV-181
AbbVie
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
05/26
05/26
NCT05650632: A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1
120
Europe, Canada, US, RoW
ABBV-383
TeneoOne Inc.
Multiple Myeloma
07/26
07/26
NCT03725007 / 2018-000715-25: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

Active, not recruiting
1
122
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494
AbbVie, AbbVie Inc.
Juvenile Idiopathic Arthritis (JIA)
05/27
05/27
NCT05259839: A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
1
270
Europe, Japan, US, RoW
ABBV-383, Dexamethasone, Lenalidomide, Pomalidomide, Nirogacestat, Daratumumab
TeneoOne Inc.
Relapsed/Refractory Multiple Myeloma
11/28
07/31
METER, NCT05444972: A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

Completed
N/A
998
Europe, Canada, US, RoW
AbbVie
Myelofibrosis
11/23
11/23
NCT05606094: Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

Completed
N/A
450
RoW
Daiichi Sankyo Co., Ltd.
Gastric Cancer
11/23
11/23
NCT04496518: Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

Recruiting
N/A
2200
Europe, US
Intrinsic Antitachycardia Pacing (iATP) Therapy
Medtronic
Ventricular Tachycardia
01/25
01/27
NCT04489225: Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

Recruiting
N/A
2200
Europe, US
Observational
Medtronic
Heart Failure
01/25
01/27
AD-VISE, NCT05081557: A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

Recruiting
N/A
975
Europe, Canada, RoW
AbbVie
Atopic Dermatitis
10/25
10/26
LIVEN, NCT05424562: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada

Recruiting
N/A
270
Canada
AbbVie
Acute Myeloid Leukemia
06/26
06/26
ASQ, NCT04024943: Personalized Therapy Study - Attain Stability Quad Post-Approval Study

Active, not recruiting
N/A
1008
Europe, US
Quadripolar LV Lead, Medtronic CRT-P, Medtronic CRT-D
Medtronic
Heart Failure
01/27
04/27
PROFUNDUS, NCT05494606: An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

Recruiting
N/A
1000
Europe, Canada, RoW
AbbVie
Ulcerative Colitis
03/28
03/28
APPRISE, NCT05841537: An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

Recruiting
N/A
1000
Europe, Canada, Japan, RoW
AbbVie
Crohn's Disease
01/28
01/28
ROSSINI, NCT06107426: Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

Recruiting
N/A
450
Europe, RoW
AbbVie
Parkinson's Disease (PD)
05/29
05/29
UPlift, NCT05930275: Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

Recruiting
N/A
1200
Europe, Canada, Japan, RoW
AbbVie
Crohn's Disease
09/28
09/28
 

Download Options